Deferasirox Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/02/2023 
17/03/2023 
SmPC 
To update section 5.1 of the SmPC to align the PI with 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
parent product to include the final report from the study to 
evaluate treatment compliance, efficacy and safety of 
deferasirox (granules) in paediatric patients with iron 
overload. Section 4.2 has been updated to include the 
different dosage between reference product and generic 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/01/2023 
17/03/2023 
SmPC and PL 
alternatives, as indicated in the PI of reference product. 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0009 
C.I.11.z - Introduction of, or change(s) to, the 
22/04/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/12/2021 
28/11/2022 
Labelling and 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PL 
IA/0008 
B.II.b.2.a - Change to importer, batch release 
24/11/2021 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0006 
Transfer of Marketing Authorisation 
12/08/2021 
01/09/2021 
SmPC, 
Labelling and 
PL 
IAIN/0005/G 
This was an application for a group of variations. 
17/03/2021 
01/09/2021 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
12/02/2021 
01/09/2021 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0003 
C.I.11.z - Introduction of, or change(s) to, the 
11/01/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/10/2020 
01/09/2021 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0001 
B.II.a.3.a.1 - Changes in the composition 
09/09/2020 
01/09/2021 
SmPC and PL 
(excipients) of the finished product - Changes in 
components of the flavouring or colouring system - 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition , deletion or replacement 
Page 4/4 
 
 
 
 
 
 
 
